"Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression and prolongsurvival, " said Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, in a statement.
While the drug combo did meet the first goal of increasing progression-free survival, it failed to prolong overall survival beyond what is normal for patients on chemotherapy without Erbitux.